Navigation Links
Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

HAYWARD, Calif., Jan. 6, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 13, 2011, at approximately 11:00 am Pacific Time.J.P. Morgan Healthcare Conference PresentationDate/Time: Thursday, January 13, at 11:00 am Pacific TimeLocation: Westin St. Francis HotelAbout Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2 or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
2. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
3. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
4. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... of the "Bioburden Testing Market by Product , ... report to their offering. The bioburden ... 2019 from $354.4 Million in 2014, growing at a ... the basis of products, the microbial limit testing market ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ... Market by Technology, Application & by Products - Global ... The global genotyping market is expected to reach ... at a CAGR of 22.3% during the forecast period ... be attributed to the availability of a range of ...
(Date:6/2/2015)... , June 2, 2015   BioClinica ® ... technology provider, today announced that David Peters , ... named Executive Vice President and Chief Financial Officer (CFO) ... Peters brings more than 25 years of ... services. "David has extensive and deep knowledge in all ...
(Date:6/2/2015)... June 2, 2015  Alere Inc. (NYSE: ... joined the White House Antibiotic Stewardship Forum today ... support and advance the President,s National Action Plan ... a number of measurable goals and objectives over ... help healthcare providers protect their patients through antibiotic ...
Breaking Biology Technology:Bioburden Testing Market 2015 - Global Forecasts to 2019 2Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2BioClinica Names David Peters New Chief Financial Officer 2Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2
... a new explanation for differences in the severity of mental illness ... more serious the handicap. The genetic defect is situated on the ... copies of the GDI1 gene that is responsible. The results are ... and are the result of work by the group of Guy ...
... Calif., Dec. 11 Marrone Bio Innovations (MBI) today ... Mr. Chris Hildreth joined MBI as Senior Vice President ... commercial aspects of the company, including sales, marketing, and ... MBI as Vice President of Process Development, and leads ...
... Dendreon Corporation (Nasdaq: DNDN ) announced today that it has ... stock at a price to the public of $24.75 per share. ... purchase up to an additional 2,250,000 shares of common stock to ... on December 15, 2009, subject to customary closing conditions. , J. ...
Cached Biology Technology:Amount of gene surplus determines severity of mental retardation in males 2Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... a species classified as vulnerable and at risk of extinction, ... or more. However, the youngest tortoises are more vulnerable, and ... study by Spanish researchers, who analysed the impact of a ... in Murcia (Spain) on these reptiles. "Tortoises can ...
... common form of malignancy in adult Caucasian populations, with more ... alone. Lifestyle risk factors but , ... to the aging structure of Western populations, and as a ... high sun exposure, which is a key risk factor for ...
... fisheries could pose a more serious threat to marine ... of Exeter, published today (19 July) in the British ... that tens of thousands of turtles from across the ... fisheries. Focusing on fisheries in Peru, the study ...
Cached Biology News:Tortoise populations can withstand fires every 30 years 2Some cutaneous HPV types may be involved in non-melanoma skin cancer development 2Study shows small-scale fisheries' impact on marine life 2
... The carbohydrate analysis standard is ... and a sugar alcohol; molecular weights ... standard is provided for use with ... carbohydrate analysis kit for column testing ...
... kit was tested on rat tissue extracts (liver, ... ( S. cerevisae ) extract. It was also ... and cell lines. Application: A simple and reliable ... based on the detection of the inorganic phosphate ...
... condition in which a lack of balance ... various antioxidants. Oxidative stress appears to ... diseases, including artherosclerosis, chronic inflammatory diseases, and ... systems that are very important for the ...
...
Biology Products: